A new AI software developed by French start-up Volta Medical for helping cardiologists treat atrial fibrillation (AF) more effectively could be commercially available within two years. The Marseille-based company told Medtech Insight that it is currently in talks to secure some Series A funding to advance development of AIFib, take it through more clinical studies and hopefully launch it in 2020.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?